MeiraGTx Holdings plc

Equities

MGTX

KYG596651029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 22/05/2024 am IST			5-day change	1st Jan Change
5.5 ^USD	-0.72%		+5.16%	-21.65%

15/05	Transcript : MeiraGTx Holdings plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
09/05	Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000	MT

MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2022

March 14, 2023 at 05:45 pm IST

MeiraGTx Holdings plc reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 129.62 million compared to USD 79.56 million a year ago. Basic loss per share from continuing operations was USD 2.87 compared to USD 1.8 a year ago.

Latest news about MeiraGTx Holdings plc

Transcript : MeiraGTx Holdings plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	15/05
Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000	09/05	MT
MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board	17/04	CI
MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Who are OpenAI's new board members?	11/03	RE
MeiraGTx to Receive $50 Million Milestone Payment from J&J's Janssen Under Bota-Vec Deal	13/02	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	22/12	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	22/12	MT
MeiraGTx Holdings Shares Rise on Sale of Remaining Bota-vec Interests to Janssen Pharmaceuticals for Up to $415 Million	21/12	MT
Janssen Pharmaceuticals, Inc. agreed to acquire Assets of MeiraGTx Holdings plc from MeiraGTx Holdings plc for approximately $130 million.	21/12	CI
MeiraGTx Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
MeiraGT Receives $30 Million Strategic Investment from Sanofi; to Seek Further Strategic Opportunities	30/23/30	MT
MeiraGTx Gets $30 Million Investment From Sanofi	30/23/30	DJ
Top Premarket Gainers	30/23/30	MT
MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.	30/23/30	CI
MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress	24/23/24	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/23/17	DJ
RBC Cuts Price Target on MeiraGTx Holdings to $11 From $13, Keeps Outperform Rating, Speculative Risk Qualifier	11/23/11	MT
MeiraGTx Holdings plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
MeiraGTx Gets Irish Regulator's Authorization for Quality Control Testing at Manufacturing Facility	19/23/19	MT
MeiraGTx Says Treatment Candidate for Dry Mouth Improved Symptoms in Phase 1 Trial	27/23/27	MT
Transcript : MeiraGTx Holdings plc - Special Call	27/23/27
MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia	27/23/27	CI

Chart MeiraGTx Holdings plc

Duration

Period

More charts

Company Profile

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MeiraGTx Holdings plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.5 USD

Average target price

21.2 USD

Spread / Average Target

+285.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEIRAGTX HOLDINGS PLC	-21.65%	354M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.30%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs